Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports

BACKGROUND: In a phase III trial of lenvatinib as first-line treatment for advanced unresectable hepatocellular carcinoma (uHCC), the drug proved non-inferior to sorafenib in terms of the overall survival, but offered better progression-free survival. However, the effects of lenvatinib in uHCC patie...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:World J Clin Cases
Hoofdauteurs: Komiyama, Satoshi, Numata, Kazushi, Moriya, Satoshi, Fukuda, Hiroyuki, Chuma, Makoto, Maeda, Shin
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Baishideng Publishing Group Inc 2020
Onderwerpen:
Case Report
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7322437/
https://ncbi.nlm.nih.gov/pubmed/32607334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12998/wjcc.v8.i12.2574
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items